BR112016008202A2 - Métodos de determinação do prognóstico do câncer de mama - Google Patents
Métodos de determinação do prognóstico do câncer de mamaInfo
- Publication number
- BR112016008202A2 BR112016008202A2 BR112016008202A BR112016008202A BR112016008202A2 BR 112016008202 A2 BR112016008202 A2 BR 112016008202A2 BR 112016008202 A BR112016008202 A BR 112016008202A BR 112016008202 A BR112016008202 A BR 112016008202A BR 112016008202 A2 BR112016008202 A2 BR 112016008202A2
- Authority
- BR
- Brazil
- Prior art keywords
- eps8l1
- amount
- breast cancer
- sample
- individual
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
MÉTODOS DE DETERMINAÇÃO DO PROGNÓSTICO DO CÂNCER DE MAMA. A presente invenção refere-se aos métodos de determinação de um diagnóstico ou prognóstico para um indivíduo com um tumor da mama. Em uma modalidade, o método inclui determinar uma quantidade de EPS8 do tipo 1 (EPS8L1) na amostra (por exemplo, uma quantidade de ácido nucleico ou proteína EPS8L1) e a comparação da quantidade de EPS8L1 na amostra com um controle. O indivíduo é determinado para ter um prognóstico pobre (tais como diminuição da probabilidade de sobrevivência), se a quantidade de EPS8L1 na amostra for aumentada em comparação com o controle. Em algumas modalidades, os métodos incluem ainda a administração de um tratamento a um indivíduo determinado para ter um mau prognóstico, tais como a administração de uma terapia de ErbB2 alvo para o indivíduo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361894548P | 2013-10-23 | 2013-10-23 | |
| PCT/US2014/061981 WO2015061577A1 (en) | 2013-10-23 | 2014-10-23 | Methods of determining breast cancer prognosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112016008202A2 true BR112016008202A2 (pt) | 2017-10-03 |
Family
ID=52993562
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016008202A BR112016008202A2 (pt) | 2013-10-23 | 2014-10-23 | Métodos de determinação do prognóstico do câncer de mama |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20160273045A1 (pt) |
| EP (1) | EP3060914A4 (pt) |
| JP (1) | JP2017501679A (pt) |
| AU (1) | AU2014339977A1 (pt) |
| BR (1) | BR112016008202A2 (pt) |
| CA (1) | CA2927617A1 (pt) |
| WO (1) | WO2015061577A1 (pt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117174338A (zh) * | 2022-05-25 | 2023-12-05 | 中国医学科学院肿瘤医院 | Her2阳性t1n0乳腺浸润性导管癌患者的复发风险预后模型 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7526387B2 (en) * | 2003-07-10 | 2009-04-28 | Genomic Health, Inc. | Expression profile algorithm and test for cancer prognosis |
| WO2006112842A2 (en) * | 2005-04-18 | 2006-10-26 | Vanandel Research Institute | Microarray gene expression profiling in classes of papillary renal cell carcinoma |
| CN103399144B (zh) * | 2008-02-25 | 2015-10-28 | 雀巢产品技术援助有限公司 | 用抗体阵列选择乳腺癌治疗药物 |
| WO2009126966A2 (en) * | 2008-04-11 | 2009-10-15 | The Regents Of The University Of California | Genetic markers indicating biological response to a plk1 kinase inhibitor |
| WO2010093379A1 (en) * | 2009-02-13 | 2010-08-19 | Fred Hutchinson Cancer Research Center | Gene expression profiling identifies genes predictive of oral squamous cell carcinoma and its prognosis |
| KR101918004B1 (ko) * | 2009-10-26 | 2018-11-13 | 애보트 모레큘러 인크. | 비-소세포 폐암의 예후를 측정하기 위한 진단 방법 |
-
2014
- 2014-10-23 BR BR112016008202A patent/BR112016008202A2/pt not_active Application Discontinuation
- 2014-10-23 EP EP14855615.2A patent/EP3060914A4/en not_active Withdrawn
- 2014-10-23 WO PCT/US2014/061981 patent/WO2015061577A1/en active Application Filing
- 2014-10-23 AU AU2014339977A patent/AU2014339977A1/en not_active Abandoned
- 2014-10-23 CA CA2927617A patent/CA2927617A1/en not_active Abandoned
- 2014-10-23 JP JP2016525610A patent/JP2017501679A/ja active Pending
- 2014-10-23 US US15/031,550 patent/US20160273045A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017501679A (ja) | 2017-01-19 |
| AU2014339977A8 (en) | 2016-05-26 |
| WO2015061577A1 (en) | 2015-04-30 |
| EP3060914A1 (en) | 2016-08-31 |
| EP3060914A4 (en) | 2017-05-17 |
| AU2014339977A1 (en) | 2016-05-19 |
| US20160273045A1 (en) | 2016-09-22 |
| CA2927617A1 (en) | 2015-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019010958A (es) | Metodos de tratamiento de tumores. | |
| BR112017020893A2 (pt) | método para o tratamento de câncer | |
| BR112016007864A2 (pt) | método para a prognose e tratamento de metástase de câncer | |
| GB2552267A (en) | Detection and treatment of disease exhibiting disease cell heterogeneity and systems and methods for communicating test results | |
| SG10201908277TA (en) | Method of determining the risk of developing breast cancer by detecting the expression levels of micrornas (mirnas) | |
| BR112012025593A2 (pt) | biomarcadores em circulação para doença | |
| BR112015023262B8 (pt) | Anticorpo isolado, imunoconjugado, formulação farmacêutica e usos do anticorpo | |
| BR112014018331A8 (pt) | Biomarcadores e terapias combinadas usando vírus oncolítico e imunomodulação | |
| BR112015031639A2 (pt) | integração alvo | |
| BR112013004673A2 (pt) | biomarcadores e métodos de tratamento. | |
| BR112014030750A2 (pt) | Método para diagnóstico, prognóstico e tratamento da metástase do câncer pulmonar | |
| SI2925888T1 (en) | Compounds and methods for the treatment of cancer | |
| BR112016004095A2 (pt) | administração de enzimas de empobrecimento de quinurenina para a terapia contra tumores | |
| BR112016002000A2 (pt) | Diagnóstico e terapia de câncer envolvendo células-tronco tumorais | |
| EA201790549A1 (ru) | Предиктивные и прогностические биомаркеры, связанные с антиангиогенной терапией злокачественной опухоли | |
| BR112017026709A2 (pt) | tratamento e diagnóstico de câncer | |
| BR112015021483A2 (pt) | arginina deiminase com reduzida reatividade cruzada para anticorpos adi-peg 20 para o tratamento do câncer | |
| BR112015008255A2 (pt) | método para o diagnóstico, prognóstico e tratamento de metástase de câncer de próstata | |
| TW201614237A (en) | Markers for identifying patients responsive to anti-PD-L1 antibody therapy | |
| BR112021009275A2 (pt) | Anticorpo humanizado anti-sirp alfa ou um fragmento de ligação a antígeno do mesmo, composição farmacêutica, molécula de ácido nucleico, e, célula hospedeira. | |
| BR112014020213A2 (pt) | biomarcadores para o diagnóstico, o prognóstico, a avaliação e a estratificação de terapia de síncope | |
| BR112015018265A2 (pt) | Composições nutricionais contendo um componente peptídico com propriedades estimulantes de adiponectina e utilizações das mesmas | |
| MY195045A (en) | Specific Biomarker Set For Non-Invasive Diagnosis of Liver Cancer | |
| BR112017001782A2 (pt) | fragmentos de anticorpo radiomarcados para uso na prevenção e/ou tratamento de câncer | |
| BR112018010669A2 (pt) | anticorpo anti-pcsk9 e utilização do mesmo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |